These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 30605231)

  • 1. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer.
    Sharma M; Holmes HM; Mehta HB; Chen H; Aparasu RR; Shih YT; Giordano SH; Johnson ML
    Cancer; 2019 Apr; 125(7):1155-1162. PubMed ID: 30605231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
    Winn AN; Keating NL; Dusetzina SB
    J Clin Oncol; 2016 Dec; 34(36):4323-4328. PubMed ID: 27998234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.
    Shen C; Zhao B; Liu L; Shih YT
    Cancer; 2018 Jan; 124(2):364-373. PubMed ID: 28976559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
    Lalani AA; McKay RR; Lin X; Simantov R; Kaymakcalan MD; Choueiri TK
    Clin Genitourin Cancer; 2017 Dec; 15(6):724-732. PubMed ID: 28645482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A questionnaire on prescription patterns of proton pump inhibitors for hemodialysis patients in Japan.
    Kawarazaki H; Nakashima A; Furusho M; Shimizu S; Nakata T
    Clin Exp Nephrol; 2020 Jun; 24(6):565-572. PubMed ID: 32147803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
    Seymour EK; Ruterbusch JJ; Winn AN; George JA; Beebe-Dimmer JL; Schiffer CA
    Cancer; 2021 Jan; 127(1):93-102. PubMed ID: 33119175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options.
    van Leeuwen RWF; Jansman FGA; Hunfeld NG; Peric R; Reyners AKL; Imholz ALT; Brouwers JRBJ; Aerts JG; van Gelder T; Mathijssen RHJ
    Clin Pharmacokinet; 2017 Jul; 56(7):683-688. PubMed ID: 28101705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients' Perceptions of Proton Pump Inhibitor Risks and Attempts at Discontinuation: A National Survey.
    Kurlander JE; Kennedy JK; Rubenstein JH; Richardson CR; Krein SL; De Vries R; Saini SD
    Am J Gastroenterol; 2019 Feb; 114(2):244-249. PubMed ID: 30694867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014).
    Landi SN; Sandler RS; Pate V; Lund JL
    Gastroenterology; 2018 Mar; 154(4):861-873.e6. PubMed ID: 29122546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deleterious association between proton pump inhibitor and protein kinase inhibitor exposure and survival for patients with lung cancer: A nationwide cohort study.
    Bordet C; Zureik M; Zelmat Y; Lafaurie M; Lapeyre-Mestre M; Sommet A; Mazieres J; Despas F
    Cancer Treat Res Commun; 2024; 39():100801. PubMed ID: 38447474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America.
    Karalexi MA; Baka M; Ryzhov A; Zborovskaya A; Dimitrova N; Zivkovic S; Eser S; Antunes L; Sekerija M; Zagar T; Bastos J; Demetriou A; Agius D; Florea M; Coza D; Polychronopoulou S; Stiakaki E; Moschovi M; Hatzipantelis E; Kourti M; Graphakos S; Pombo-de-Oliveira MS; Adami HO; Petridou ET
    Eur J Cancer; 2016 Nov; 67():183-190. PubMed ID: 27677054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib.
    Ruanglertboon W; Sorich MJ; Logan JM; Rowland A; Hopkins AM
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2693-2697. PubMed ID: 32449002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
    Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
    J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Community-dwelling older adults' awareness of the inappropriate use of proton pump inhibitors.
    Rababa M; Rababa'h A
    BMC Geriatr; 2020 Oct; 20(1):431. PubMed ID: 33121444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton pump inhibitors: the good, the bad, and the unwanted.
    Chubineh S; Birk J
    South Med J; 2012 Nov; 105(11):613-8. PubMed ID: 23128806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer.
    Wong GG; Ha V; Chu MP; Dersch-Mills D; Ghosh S; Chambers CR; Sawyer MB
    Clin Colorectal Cancer; 2019 Mar; 18(1):72-79. PubMed ID: 30551953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Use and Misuse of Proton Pump Inhibitors: An Opportunity for Deprescribing.
    Dharmarajan TS
    J Am Med Dir Assoc; 2021 Jan; 22(1):15-22. PubMed ID: 33321078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.
    Lau YY; Gu W; Lin T; Viraswami-Appanna K; Cai C; Scott JW; Shi M
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1119-1128. PubMed ID: 28424965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.
    Buti S; Tommasi C; Scartabellati G; De Giorgi U; Brighi N; Rebuzzi SE; Puglisi S; Caffo O; Kinspergher S; Mennitto A; Cattrini C; Santoni M; Verzoni E; Rametta A; Stellato M; Malgeri A; Roviello G; de Filippo M; Cortellini A; Bersanelli M
    Anticancer Drugs; 2023 Jan; 34(1):178-186. PubMed ID: 36539370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.